JP2022518150A5 - - Google Patents
Info
- Publication number
- JP2022518150A5 JP2022518150A5 JP2021539400A JP2021539400A JP2022518150A5 JP 2022518150 A5 JP2022518150 A5 JP 2022518150A5 JP 2021539400 A JP2021539400 A JP 2021539400A JP 2021539400 A JP2021539400 A JP 2021539400A JP 2022518150 A5 JP2022518150 A5 JP 2022518150A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061674A JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789462P | 2019-01-07 | 2019-01-07 | |
| US62/789,462 | 2019-01-07 | ||
| US201962845829P | 2019-05-09 | 2019-05-09 | |
| US62/845,829 | 2019-05-09 | ||
| PCT/US2020/012637 WO2020146432A1 (en) | 2019-01-07 | 2020-01-07 | Use of an anti-cd45 antibody drug conjugate (adc) in cell therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061674A Division JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518150A JP2022518150A (ja) | 2022-03-14 |
| JPWO2020146432A5 JPWO2020146432A5 (https=) | 2023-01-19 |
| JP2022518150A5 true JP2022518150A5 (https=) | 2023-01-19 |
Family
ID=71520485
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539400A Pending JP2022518150A (ja) | 2019-01-07 | 2020-01-07 | 細胞療法での抗ｃｄ４５抗体－薬物結合体（ａｄｃ）の使用経験 |
| JP2025061674A Pending JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061674A Pending JP2025111482A (ja) | 2019-01-07 | 2025-04-03 | 細胞治療における抗ｃｄ４５抗体薬物コンジュゲート（ａｄｃ）の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220062339A1 (https=) |
| EP (1) | EP3908296A4 (https=) |
| JP (2) | JP2022518150A (https=) |
| CN (1) | CN113490504A (https=) |
| AU (1) | AU2020206117A1 (https=) |
| CA (1) | CA3125751A1 (https=) |
| WO (1) | WO2020146432A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022040088A2 (en) * | 2020-08-21 | 2022-02-24 | Synthekine, Inc. | Cd45 binding molecules and methods of use |
| GB202015226D0 (en) * | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
| GB202015235D0 (en) | 2020-09-25 | 2020-11-11 | Ucl Business Plc | Anti-CD45 antibodies and related therapeutics |
| WO2022081486A1 (en) * | 2020-10-12 | 2022-04-21 | Sorrento Therapeutics, Inc. | Cd19-directed chimeric antigen receptor constructs |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| HK1249534A1 (zh) * | 2015-04-06 | 2018-11-02 | 哈佛大学校长及研究员协会 | 用於非清髓性预处理的组合物和方法 |
| IL295224B2 (en) * | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| CN107708741A (zh) * | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| ES2887273T3 (es) * | 2015-06-29 | 2021-12-22 | Immunogen Inc | Anticuerpos anti-CD123 y conjugados y derivados de los mismos |
| EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| CA3117367A1 (en) * | 2018-10-30 | 2020-05-07 | Magenta Therapeutics, Inc. | Anti-cd45 antibodies and conjugates thereof |
-
2020
- 2020-01-07 CA CA3125751A patent/CA3125751A1/en active Pending
- 2020-01-07 WO PCT/US2020/012637 patent/WO2020146432A1/en not_active Ceased
- 2020-01-07 EP EP20739127.7A patent/EP3908296A4/en active Pending
- 2020-01-07 AU AU2020206117A patent/AU2020206117A1/en active Pending
- 2020-01-07 CN CN202080017259.0A patent/CN113490504A/zh active Pending
- 2020-01-07 JP JP2021539400A patent/JP2022518150A/ja active Pending
-
2021
- 2021-07-06 US US17/368,815 patent/US20220062339A1/en active Pending
-
2025
- 2025-04-03 JP JP2025061674A patent/JP2025111482A/ja active Pending